Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells

Anti-Cancer Drugs

Volumn 13, Issue 10, 2002, Pages 1031-1042

  Dvorakova, Katerina ^b   Payne, Claire M ^b   Landowski, Terry H ^a   Tome, Margaret E ^c   Halperin, Daniel S ^a   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase; Imexon; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS LIGAND; IMEXON; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIPLE MYELOMA; MYELOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HEXANONES; HUMANS; MICROSCOPY, CONFOCAL; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 12244256084     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211000-00007     Document Type: Article

References (49)

1. Salmon SE, Hersh EM. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay [see Comments]. J Natl Cancer Inst 1994; 86: 228-30.
2. Sagaster P, Kokoschka EM, Kokron O, Micksche M. Antitumor activity of imexon [Letter; Comment]. J Natl Cancer Inst 1995; 87: 935-6.
3. Bicker UF. Bm06 002: A new immunostimulating compound. In: Chirigos MA, ed. Immune Modulation and Control of Neoplasia by Adjuvant Therapy. New York: Raven Press 1978: 389-1.
4. Dorr RT, Liddil JD, Klein MK, Hersh EM. Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs 1995; 13: 113-6.
5. Micksche M, Kokoschka EM, Sagaster P, Bicker U. Phase I study for a new immunornodulating drug, BM 06 002, in man. In: Chirigos MA, ed. Immune Modulation and Control of Neoplasia by Adjuvant Therapy. New York: Raven Press 1978: 403-13.
6. Mead JR, Burger RA, Morrey JD, Warren RP, Okleberry KM, Sidwell RW. Effect of immunomodulators in the hu-PBL-SCID mouse model. Biotechnol Ther 1993; 4: 133-43.
7. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 2000; 60: 749-58.
8. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001; 97: 3544-51.
9. Dvorakova K, Payne CM, Tome ME, et al. Molecular and cellular characterization of RPMI8226 myeloma cells resistant to imexon. Mol Cancer Ther 2001; 1: 185-95.
10. Sordet O, Rebe C, Leroy I, et al. Mitochondriatargeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 2001; 97: 3931-40.
11. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000; 5: 155-8.
12. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? [Editorial; Comment]. J Natl Cancer Inst 1999; 91: 743-5.
13. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-70.
14. Larochette N, Decaudin D, Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999; 249: 413-21.
15. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999; 16: 58-64.
16. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-11.
17. Thornberry NA. Caspases: Key mediators of apoptosis. Chem Biol 1998; 5: R 97-3.
18. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001; 92: 57-70.
19. L prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-63.
20. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-92.
21. Granville DJ, Carthy CM, Jiang H, Shore GC, McManus BM, Hunt DW. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 1998; 437: 5-10.
22. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-31.
23. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-7.
24. Polster BM, Kinnally KW, Fiskum G. BH3 death domain peptide induces cell-type selective mitochondrial outer membrane permeability. J Biol Chem 2001; 1: 1.
25. Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000; 14: 830-40.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
27. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
28. L regulates the membrane potential and volume homeostasis of mitochondria [see Comments]. Cell 1997; 91: 627-37.
29. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem 1987 May 15; 163: 279]. Anal Biochem 1985; 150: 76-85.
30. + precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate. Cell Death Different 2000; 7: 314-26.
31. Payne CM, Crowley C, Washo-Stultz D, et al. The stress-response proteins poly(ADP-ribose) polymerase and NF-kappaB protect against bile salt-induced apoptosis. Cell Death Different 1998; 5: 623-36.
32. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-72.
33. Tauskela JS, Hewitt K, Kang LP, et al. Evaluation of glutathione-sensitive fluorescent dyes in cortical culture. Glia 2000; 30: 329-41.
34. Lantz RC, Lemus R, Lange RW, Karol MH. Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of toluene diisocyanate. Toxicol Sci 2001; 60: 348-55.
35. Macho A, Decaudin D, Castedo M, et al. Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis [see Comments]. Cytometry 1996; 25: 333-40.
36. Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85: 3566-76.
37. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-70.
38. Robertson MJ, Manley TJ, Pichert G, et al. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymph 1995; 17: 51-61.
39. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757-64.
40. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998; 102: 1055-60.
41. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-61.
42. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383-91.
43. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
44. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
45. L form cytochrome c-conducting pores in pure lipid membranes. J Biol Chem 2001; 276: 31083-91.
46. Gottlieb IRA. Mitochondria: Execution central. FEBS Lett 2000; 482: 6-12.
47. Marzo I, Brenner C, Zamzami N, et al. The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins. J Exp Med 1998; 187: 1261-71.
48. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-5.
49. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.